| abstract |
Provided by the present invention is a pharmaceutical composition, which comprises HS-25 and an HMG-CoA reductase inhibitor, and which may further comprise one or more auxiliary materials from among calcium carbonate, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, sodium lauryl sulfate, polysorbate, cross-linked sodium carboxymethyl cellulose, cross-linked povidone, microcrystalline cellulose, povidone, hydroxypropyl cellulose, lactose, pregelatinized starch, magnesium stearate and talc. The composition may be made into a variety of dosage forms, and a preparation thereof has good stability and controllable quality. |